|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Nordlinger B, Adam R, Köhne
CH, Pozzo C, Poston G, Ychou M and Rougier P: European Colorectal
Metastases Treatment Group: Towards a pan-European consensus on the
treatment of patients with colorectal liver metastases. Eur J
Cancer. 42:2212–2221. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stangl R, Altendorf-Hofmann A, Charnley RM
and Scheele J: Factors influencing the natural history of
colorectal liver metastases. Lancet. 343:1405–1410. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gallagher DJ and Kemeny N: Metastatic
colorectal cancer: From improved survival to potential cure.
Oncology. 78:237–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Helling TS and Martin M: Cause of death
from liver metastases in colorectal cancer. Ann Surg Oncol.
21:501–506. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xing M, Kooby DA, El-Rayes BF, Kokabi N,
Camacho JC and Kim HS: Locoregional therapies for metastatic
colorectal carcinoma to the liver - an evidence-based review. J
Surg Oncol. 110:182–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kennedy A, Coldwell D, Sangro B, Wasan H
and Salem R: Radioembolization for the treatment of liver tumors
general principles. Am J Clin Oncol. 35:91–99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sato KT, Lewandowski RJ, Mulcahy MF,
Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A III,
Mandal R, et al: Unresectable chemorefractory liver metastases:
Radioembolization with 90Y microspheres - safety,
efficacy, and survival. Radiology. 247:507–515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hickey R, Lewandowski RJ, Prudhomme T,
Ehrenwald E, Baigorri B, Critchfield J, Kallini J, Gabr A,
Gorodetski B, Geschwind JF, et al: 90Y Radioembolization
of colorectal hepatic metastases using glass microspheres: Safety
and survival outcomes from a 531-patient multicenter study. J Nucl
Med. 57:665–671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maleux G, Deroose C, Laenen A, Verslype C,
Heye S, Haustermans K, De Hertogh G, Sagaert X, Topal B, Aerts R,
et al: Yttrium-90 radioembolization for the treatment of
chemorefractory colorectal liver metastases: Technical results,
clinical outcome and factors potentially influencing survival. Acta
Oncol. 55:486–495. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Hazel GA, Heinemann V, Sharma NK,
Findlay MP, Ricke J, Peeters M, Perez D, Robinson BA, Strickland
AH, Ferguson T, et al: SIRFLOX: Randomized phase III trial
comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus
mFOLFOX6 (plus or minus bevacizumab) plus selective internal
radiation therapy in patients with metastatic colorectal cancer. J
Clin Oncol. 34:1723–1731. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Linnekamp JF, Wang X, Medema JP and
Vermeulen L: Colorectal cancer heterogeneity and targeted therapy:
A case for molecular disease subtypes. Cancer Res. 75:245–249.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Migliore L, Migheli F, Spisni R and
Coppedè F: Genetics, cytogenetics, and epigenetics of colorectal
cancer. J Biomed Biotechnol. 2011:7923622011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Waring P, Tie J, Maru D and Karapetis CS:
RAS mutations as predictive biomarkers in clinical management of
metastatic colorectal cancer. Clin Colorectal Cancer. 15:95–103.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Osumi H, Shinozaki E, Suenaga M, Matsusaka
S, Konishi T, Akiyoshi T, Fujimoto Y, Nagayama S, Fukunaga Y, Ueno
M, et al: RAS mutation is a prognostic biomarker in colorectal
cancer patients with metastasectomy. Int J Cancer. 139:803–811.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Andreyev HJ, Norman AR, Cunningham D,
Oates JR and Clarke PA: Kirsten ras mutations in patients with
colorectal cancer: The multicenter ‘RASCAL’ study. J Natl Cancer
Inst. 90:675–684. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hutchins G, Southward K, Handley K, Magill
L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M,
Kerr D, et al: Value of mismatch repair, KRAS, and BRAF mutations
in predicting recurrence and benefits from chemotherapy in
colorectal cancer. J Clin Oncol. 29:1261–1270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lahti SJ, Xing M, Zhang D, Lee JJ,
Magnetta MJ and Kim HS: KRAS status as an independent prognostic
factor for survival after Yttrium-90 radioembolization therapy for
unresectable colorectal cancer liver metastases. J Vasc Interv
Radiol. 26:1102–1111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Spindler KL, Appelt AL, Pallisgaard N,
Andersen RF, Brandslund I and Jakobsen A: Cell-free DNA in healthy
individuals, noncancerous disease and strong prognostic value in
colorectal cancer. Int J Cancer. 135:2984–2991. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
El Messaoudi S, Mouliere F, Du Manoir S,
Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau
F, Theillet C, et al: Circulating DNA as a strong multi-marker
prognostic tool for metastatic colorectal cancer patient management
care. Clin Cancer Res. 22:3067–3077. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Spindler KL, Pallisgaard N, Vogelius I and
Jakobsen A: Quantitative cell-free DNA, KRAS, and BRAF mutations in
plasma from patients with metastatic colorectal cancer during
treatment with cetuximab and irinotecan. Clin Cancer Res.
18:1177–1185. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Umetani N, Giuliano AE, Hiramatsu SH,
Amersi F, Nakagawa T, Martino S and Hoon DS: Prediction of breast
tumor progression by integrity of free circulating DNA in serum. J
Clin Oncol. 24:4270–4276. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mouliere F, El Messaoudi S, Pang D,
Dritschilo A and Thierry AR: Multi-marker analysis of circulating
cell-free DNA toward personalized medicine for colorectal cancer.
Mol Oncol. 8:927–941. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pang D, Winters TA, Jung M, Purkayastha S,
Cavalli LR, Chasovkikh S, Haddad BR and Dritschilo A:
Radiation-generated short DNA fragments may perturb non-homologous
end-joining and induce genomic instability. J Radiat Res (Tokyo).
52:309–319. 2011. View Article : Google Scholar
|
|
27
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC, et al: New guidelines to evaluate the
response to treatment in solid tumors. European Organization for
Research and Treatment of Cancer, National Cancer Institute of the
United States, National Cancer Institute of Canada. J Natl Cancer
Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Spindler KL, Pallisgaard N, Andersen RF,
Ploen J and Jakobsen A: Gemcitabine and capecitabine for heavily
pre-treated metastatic colorectal cancer patients - a phase II and
translational research study. Anticancer Res. 34:845–850.
2014.PubMed/NCBI
|
|
30
|
Adam R, Pascal G, Castaing D, Azoulay D,
Delvart V, Paule B, Levi F and Bismuth H: Tumor progression while
on chemotherapy: A contraindication to liver resection for multiple
colorectal metastases? Ann Surg. 240:1052–1064. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS,
and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy
in chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sorich MJ, Wiese MD, Rowland A,
Kichenadasse G, McKinnon RA and Karapetis CS: Extended RAS
mutations and anti-EGFR monoclonal antibody survival benefit in
metastatic colorectal cancer: A meta-analysis of randomized,
controlled trials. Ann Oncol. 26:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Andreyev HJ, Norman AR, Cunningham D,
Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N,
et al: Kirsten ras mutations in patients with colorectal cancer:
The ‘RASCAL II’ study. Br J Cancer. 85:692–696. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Richman SD, Seymour MT, Chambers P,
Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH and Quirke P:
KRAS and BRAF mutations in advanced colorectal cancer are
associated with poor prognosis but do not preclude benefit from
oxaliplatin or irinotecan: Results from the MRC FOCUS trial. J Clin
Oncol. 27:5931–5937. 2009. View Article : Google Scholar : PubMed/NCBI
|
